The role of PET-CT in decision making on the treatment of localized nodular form of pulmonary AL-amyloidosis

Česká verzia

Authors: Z. Adam ¹; M. Elleder ²; M. Moulis ³; M. Tichý ⁴; I. Červinková ⁵; Z. Řehák ⁶; R. Koukalová ⁶; Z. Fojtík ¹; I. Hanke ⁷; L. Pour ¹; M. Krejčí ¹; L. Zahradová ¹; P. Szturz ¹; R. Hájek ¹; Z. Král ¹; J. Mayer ¹
Authors place of work: Interní hematoonkologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jiří Mayer, CSc. ¹; Ústav dědičných metabolických poruch 1. lékařské fakulty UK a VFN Praha, přednosta doc. MUDr, . Viktor Kožich, CSc. ²; Radiodiagnostická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednostka doc. MUDr. Jarmila Skotáková, Ph. D. ³; Ústav patologie Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta doc. MUDr. Josef Feit, CSc. ⁴; Oddělení patologie, Lékařské fakulty UP a FN Olomouc, přednosta doc. MUDr. Martin Tichý, CSc. ⁵; Oddělení nukleární medicíny, centrum PET Masarykova onkologického ústavu Brno, přednosta prim. MUDr. Karol Bolčák ⁶; Chirurgická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Zdeněk Kala, CSc. ⁷
Published in the journal: Vnitř Lék 2012; 58(3): 241-252
Category: Case Reports

Summary

Depending on the extent of organism affected, there is a systemic (amyloid is deposited in the interstitial space of multiple tissues and organs) and localized (amyloid is deposited in one or a few solitary lesions) form of amyloidosis. Localized forms of amyloidosis have a significantly better prognosis than the systemic ones. The respiratory tract might be affected by diffuse interstitial involvement, associated with systemic AL-amyloidosis, as well as localised involvement of respiratory tract (localised laryngotracheobronchial amyloidosis) or pulmonary parenchyma called nodular form of localized pulmonary amyloidosis. Tracheobronchial form may affect larynx and bronchial tree, and forms plaques or nodules in the epithelium of the respiratory tract. Nodular form causes spherical or irregular lesions in the pulmonary parenchyma, indistinguishable from pulmonary parenchyma metastases. We describe a two-year follow up of a patient with nodular form of pulmonary amyloidosis. The patient had multiple lesions in both lungs, clearly visible on HRCT (High Resolution Computer Tomography) that intensively accumulated fluorodeoxyglucose (FDG) during the first PET-CT. At the time of diagnosis, the largest lesion SUV for FDG accumulation was 8.2. Histochemical analysis showed that amyloid consisted of the light λ chains, i.e. AL-amyloid. Investigations to detect a systemic form of amyloidosis, if present, were negative. The patient had no monoclonal immunoglobulin either in the urine or serum (negative immunofixation) and had normal levels of free light chains in the serum. Her symptoms were previously suggestive of the Sjögren’s syndrome. However, the rheumatologist consulted at the time of diagnosis of the nodular form of pulmonary amyloidosis did not find any signs of an active systemic connective tissue disorder. CRP was repeatedly normal. When systemic AL-amyloidosis was excluded, we decided to only monitor lesion development with no treatment intervention. The patient had 3 PET-CTs. CT showed that no lesions enlarged, some lesions decreased in size slightly. It should be emphasized that follow-up PET-CTs did not show increased FDG accumulation. We assume that the increased FDG accumulation in pulmonary lesions seen during the first PET-CT was due to the activity of the cells that formed this amyloid and that this activity spontaneously ceased, leading to normalization of FDG accumulation in pulmonary nodules. PET-CT is useful for monitoring of the development of pulmonary nodular amyloidosis. Normalization of originally increased FDG accumulation in amyloid lesions suggests cessation of the process of amyloid formation and is a positive prognostic sign.

Key words:
localized amyloidosis – nodular pulmonary amyloidosis – tracheobronchial amyloidosis – AL-amyloidosis – PET-CT imagination – multiple myeloma

Zdroje

1. Ščudla V, Pika T. Současné možnosti diagnostiky a léčby systémové AL-amyloidózy. Vnitř Lék 2009; 55 (Suppl 1): S77–S84.

2. Sideras K, Gerz MA. Amyloidosis. Adv Clin Chem 2009; 47: 1–44.

3. Adam Z, Ščudla V. Clinical manifestations of AL-amyloidosis and some othertypes of amyloidosis. Vnitř Lék 2001; 47: 36–45.

4. Adam Z, Ščudla V, Tomíska M. Léčba AL--amyloidózy a některých dalších typů amyloidóz. Vnitř Lék 2001; 47: 46–52.

5. Džingozovová M, Skričková J, Mačák J et al. Lokalizovaná forma tracheobronchiální amyloidózy AA-typu, a její odlišení od systémové formy mayloidózy v klinické praxi. Vnitř Lék 2009; 55: 593–598.

6. Kuchyňka P, Paleček T, Šimek S et al. The isolated form of cardiac amyloidosis in the form of beginning infiltrative cardiomyopathy without restrictive physiology. Vnitř Lék 2008; 54: 1010–1013.

7. Krejčí J. Cardiac amyloidosis – an underestimated threat? Vnitř Lék 2008; 54: 950–951.

8. Biewend ML, Menke DM, Calamia KT. The spectrum of localized amyloidosis: a case series of 20 patients and review of the literature. Amyloid 2006; 13: 135–142.

9. Adam Z, Pour L, Krejcí M et al. Poškození ledvin u mnohočetného myelomu a u dalších monoklonálních gamapatií. Vnitř Lék 2008; 54: 847–861.

10. Westlake S, Edwards CJ. Pulmonary nodular amyloidosis and systemic lupus erythematosus. Lupus 2005; 14: 639–640.

11. Georghiou GP, Boikov O, Vidne BA et al. Primary pulmonary amyloidosis due to low-grade B cell lymphoma. Asian Cardiovasc Thorac Ann 2007; 15: 69–71.

12. Lim JK, Lacy MQ, Kurtin PJ et al. Pulmonary marginal zone lymphoma of MALT type as a cause of localised pulmonary amyloidosis. J Clin Pathol 2001; 54: 642–646.

13. Michaels L, Hyams VJ. Amyloid in localised deposits and plasmacytomas of the respiratory tract. J Pathol 1979; 128: 29–38.

14. Ihling C, Weirich G, Gaa A et al. Amyloid tumors of the lung – an immunocytoma? Pathol Res Pract 1996; 192: 446–452.

15. King CS, Holley AB, Sherner JH. Severe bullous lung disease due to marginal-zone-lymphoma-associated amyloidosis. Respir Care 2008; 53: 1495–1498.

16. Satani T, Yokose T, Kaburagi T et al. Amyloid deposition in primary pulmonary marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Pathol Int 2007; 57: 746–750.

17. Wieker K, Röcken C, Koenigsmann M et al. Pulmonary low-grade MALT-lymphoma associated with localized pulmonary amyloidosis. A case report. Amyloid 2002; 9: 190–193.

18. Nakamura N, Yamada G, Itoh T et al. Pulmonary MALT lymphoma with amyloid production in a patient with primary Sjögren’s syndrome. Intern Med 2002; 41: 309–311.

19. Sugai S. Mucosa-associated lympoid tissue (MALT) lymphoma and primary amyloidosis in the lung in Sjögren’s syndrome. Intern Med 2002; 41: 251–252.

20. Khoor A, Myers JL, Tazelaar HD et al. Amyloid-like pulmonary nodules, including localized light-chain deposition: clinicopathologic analysis of three cases. Am J Clin Pathol 2004; 121: 200–204.

21. Miyamoto T, Kobayashi T, Makiyama M et al. Monoclonality of infiltrating plasma cells in primary pulmonary nodular amyloidosis: detection with polymerase chain reaction. J Clin Pathol 1999; 52: 464–467.

22. Ross P Jr, Magro CM. Clonal light chain restricted primary intrapulmonary nodular amyloidosis. Ann Thorac Surg 2005; 80: 344–347.

23. Stokes MB, Jagirdar J, Burchstin O et al. Nodular pulmonary immunoglobulin light chain deposits with coexistent amyloid and nonamyloid features in an HIV-infected patient. Mod Pathol 1997; 10: 1059–1065.

24. Kaplan B, Martin BM, Boykov O et al. Co-deposition of amyloidogenic immunoglobulin light and heavy chains in localized pulmonary amyloidosis. Virchows Arch 2005; 447: 756–761.

25. Yanagawa N, Ogata SY, Motoyama T. Pulmonary localized AA type amyloidosis with cyst-like structures and marginal zone B-cell lymphoma of the MALT type coexisting independently in the left upper lung. Intern Med 2008; 47: 1529–1533.

26. Shah PL, Gillmore JD, Copley SJ et al. The importance of complete screening for amyloid fibril type and systemic disease in patients with amyloidosis in the respiratory tract. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 134–142.

27. Rostagno A, Frizzera G, Ylagan L et al. Tumoral non-amyloidotic monoclonal immunoglobulin light chain deposits (“aggregoma”): presenting feature of B-cell dyscrasia in three cases with immunohistochemical and biochemical analyses. Br J Haematol 2002; 119: 62–69.

28. Okuda M, Okuda Y, Ogura T et al. Primary lung involvement with amyloid deposition in Waldenstöm’s macroglobulinemia: observations from over 20 years. Respirology 2004; 9: 414–418.

29. Beji M, Louzir B, Haouet S et al. Primary localized bronchopulmonary amyloidosis. Rev Pneumol Clin 1996; 52: 36–38.

30. Berk JL, O’Regan A, Skinner M. Pulmonary and tracheobronchial amyloidosis. Semin Respir Crit Care Med 2002; 23: 155–165.

31. Cordier JF. Pulmonary amyloidosis in hematological disorders. Semin Respir Crit Care Med 2005; 26: 502–513.

32. Lachmann HJ, Hawkins PN. Amyloidosis and the lung. Chron Respir Dis 2006; 3: 203–214.

33. Miura K, Shirasawa H. Lambda III subgroup immunoglobulin light chains are precursor proteins of nodular pulmonary amyloidosis. Am J Clin Pathol 1993; 100: 561–566.

34. Pitz MW, Gibson IW, Johnston JB. Isolated pulmonary amyloidosis: case report and review of the literature. Am J Hematol 2006; 81: 212–213.

35. Xu L, Cai BQ, Zhong X et al. Respiratory manifestations in amyloidosis. Chin Med J (Engl) 2005; 118: 2027–2033.

36. Utz JP, Swensen SJ, Gertz MA. Pulmonary amyloidosis. The Mayo Clinic experience from 1980 to 1993. Ann Intern Med 1996; 124: 407–413.

37. Howard ME, Ireton J, Daniels F et al. Pulmonary presentations of amyloidosis. Respirology 2001; 6: 61–64.

38. Šterclová M, Matěj R. Difuzní plicní amyloidóza jako příčina recidivujícího fluidothoraxu. Kazuistiky v pneumologii 2006; 3: 4–8.

39. Cordier JF, Loire R, Brune J. Amyloidosis of the respiratory tract. Clinical and pathologic features in a series of 21 patients. Chest 1989; 90: 827–231.

40. Lewinsohn G, Bruderman I, Bohdana A. Primary difuse pulmonary amyloidosis with monoclonal gammopathy. Chest 1976; 69: 682–685.

41. Smith RR, Hutchins GM, Moore GW et al. Type and distribution of pulmonary parenchymal and vascular anuloid. Correlation with cardiac amyloidosis. Am J Med 1979; 66: 96–104.

42. Celli BR, Rubinow A, Cohen AS et al. Patterns of pulmonary involvement in systemic amyloidosis. Chest 1978; 74: 543–547.

43. Romero Candeira S, Martín Serrano C, Hernandez Blasco L. Amyloidosis and pleural disease. Chest 1991; 100: 292–293.

44. Berk JL, Keane J, Seldin DC et al. Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis. Chest 2003; 124: 969–977.

45. Berk JL, Wiesman JF, Skinner M et al. Diaphragm paralysis in primary systemic amyloidosis. Amyloid 2005; 12: 193–196.

46. Berk JL. Pleural effusions in systemic amyloidosis. Curr Opin Pulm Med 2005; 11: 324–328.

47. Duygu H, Akilli A, Ozerkan F et al. Primary cardiac amyloidosis mimicking interstitial lung disease and bleeding diathesis: a case report. Heart Surg Forum 2007; 10: E177–E179.

48. Cottin V, Cordier JF. Interstitial pulmonary amyloidosis. Respiration 2008; 75: 210.

49. Doshi A, Rodrigues M, Deshpande R et al. Spontaneous resolution of diffuse alveolar septal amyloidosis. Indian J Chest Dis Allied Sci 2001; 43: 177–179.

50. Ege E, Uzaslan E, Ursavaş A et al. Primary pulmonary amyloidosis associated with multiple myeloma. Tuberk Toraks 2006; 54: 65–70.

51. Haydar AA, Li A, Hilton R et al. Eosinophilia and symptomatic pulmonary amyloidosis. Postgrad Med J 2004; 80: 738–739.

52. Hess T, Egerer G, Kasper B et al. Atypical manifestations of multiple myeloma: radiological appearance. Eur J Radiol 2006; 58: 280–285.

53. Chim CS, Wong M, Fan Y. Pulmonary interstitial amyloidosis complicating multiple myeloma. J Clin Oncol 2008; 26: 504–506.

54. Vervaet V, Smeets P, Verstraete K. Diffuse amyloidosis of the lung associated with multiple myeloma. JBR-BTR 2003; 86: 176–177.

55. Dingli D, Utz JP, Gertz MA. Pulmonary hypertension in patients with amyloidosis. Chest 2001; 120: 1735–1738.

56. Eder L, Zisman D, Wolf R et al. Pulmonary hypertension and amyloidosis – an uncommon association: a case report and review of the literature. J Gen Intern Med 2007; 22: 416–419.

57. Lehtonen J, Kettunen P. Pulmonary hypertension as a dominant clinical picture in a case of amyloidosis and smoldering multiple myeloma. Int J Cardiol 2007; 115: e29–e30.

58. Sterlacci W, Veits L, Moser P et al. Idiopathic systemic amyloidosis primarily affecting the lungs with fatal pulmonary haemorrhage due to vascular involvement. Pathol Oncol Res 2009; 15: 133–136.

59. Boyd King A, Sharma O, Stevenson K. Localized interstitial pulmonary amyloid: a case report and review of the literature. Curr Opin Pulm Med 2009; 15: 517–520.

60. Fujimoto N, Masuoka H, Kosaka H et al. Primary amyloidosis with pulmonary involvement which presented exudative pleural effusion and high fever. Intern Med 2003; 42: 756–760.

61. Orriols R, Aliaga JL, Rodrigo MJ et al. Localised alveolar-septal amyloidosis with hypersensitivity pneumonitis. Lancet 1992; 339: 1261–1262.

62. Poh SC, Tria TS, Seah HC. Primary difuse alveolar septal amyloidosis. Torax 1975; 30: 186–191.

63. Cazalets C, Belleguic C, Sost G et al. Tracheobronchial amyloidosis: apropos of 2 cases. Rev Med Interne 2002; 23: 317–321.

64. Daniels JT, Cury JD, Diaz J. An unusual cause of postobstructive pneumonia. Chest 2007; 131: 930–933.

65. Deutschmann HA, Schwarz T, Schoellnast H et al. Isolated tracheobronchial amyloidosis: a rare cause of a hilar space-occupying lesion. Rofo 2006; 178: 1264–1266.

66. Hanon S, De Keukeleire T, Dieriks B et al. Primary tracheobronchial amyloidosis: a series of 3 cases. Acta Clin Belg 2007; 62: 56–60.

67. Hui AN, Koss MN, Hochholzer L et al. Amyloidosis presenting in the lower respiratory trakt. Clinicopathologic, radiologic, immunohistochemical, and histochemical studies on 48 cases. Arch Pathol Lab Med 1986; 110: 212–218.

68. Minogue SC, Morrisson M, Ansermino M. Laryngo-tracheo-bronchial stenosis in a patient with primary pulmonary amyloidosis: a case report and brief review. Can J Anaesth 2004; 51: 842–845.

69. Peterman W, Barth J, Schlüter E. Localised amyloidosis of central airweys. Eur J Respir Dis 1987; 71: 210–212.

70. Racil H, Ben Amar J, Rouhou SC et al. Haemoptysis revealing tracheobronchial amyloidosis. Rev Pneumol Clin 2011; 67: 109–112.

71. Rubinow A, Celli BR, Cohen AS et al. Localised amyloidosis of the respiratory tract. Am Rev Respir Dis 1978; 118: 212–218.

72. Thomson PJ, Citron KM. Amyloid and the lower respiratory tract. Torax 1983; 38: 84–87.

73. Yamazaki S, Kanda S, Yasuo M et al. Laryngo-tracheo-bronchial amyloidosis presenting severe airway stenosis. Intern Med 2006; 45: 1021–2022.

74. Breitenfelder M, Kusch E, Leichsenring M et al. Pulmonary nodular amyloidosis mimicking multiple pulmonary metastases of carcinoma of the corpus uteri. Chirurg 2001; 72: 1062–1066.

75. Cotton RE, Jackson JW. Localized amyloid tumour’s of the lung simulating malignant neoplasmasms. Thorax 1964; 19: 97–103.

76. Gaurav K, Panda M. An uncommon cause of bilateral pulmonary nodules in a long-term smoker. J Gen Intern Med 2007; 22: 1617–1620.

77. Holme S Desal JBN, Sapsford RN. Nodular pulmonary amyloidosis. A case report and review of the literature. Br J Dis Chest 1988; 82: 414–417.

78. Kos S, Savic S, Steinbrich W. Nodular form of primary pulmonary amyloidosis. Rofo 2007; 179: 1277–1279.

79. Papla B, Rudnicka L. Primary amyloid tumors of the lungs – six cases. Pol J Pathol 2005; 56: 197–202.

80. Pusztaszeri M, Kamel EM, Artemisia S et al. Nodular pseudotumoral pulmonary amyloidosis mimicking pulmonary carcinoma. Thorax 2005; 60: 440.

81. Seith A, Kumar J, Hari S et al. Isolated nodular pulmonary amyloidosis. Intern Med J 2008; 38: 293–294.

82. Siong Chuan L, Johnson HA. Multiple nodular pulmonary amyloidosis. Torax 1975; 30: 178–185.

83. Skagseth E Jr, Normann T. Localized amyloid tumour of the lung. Scand J Thorac Cardiovasc Surg 1970; 4: 135–138.

84. Suzuki H, Matsui K, Hirashima T et al. Three cases of the nodular pulmonary amyloidosis with a longterm observation. Intern Med 2006; 45: 283–286.

85. Tokunaga T, Takeda S, Sawabata N et al. Nodular pulmonary amyloidosis. Jpn J Thorac Cardiovasc Surg 2006; 54: 399–401.

86. Calatayud J, Candelas G, Gómez A et al. Nodular pulmonary amyloidosis in a patient with rheumatoid arthritis. Clin Rheumatol 2007; 26: 1797–1798.

87. Niepolski L, Grzegorzewska AE, Szymaś J. Nodular pulmonary amyloidosis and Sjögren’s syndrome in a patient treated with intermittent hemodialysis. Hemodial Int 2007; 11: 406–410.

88. Rodrigues K, Neves FS, Stoeterau KB et al. Pulmonary amyloidosis in Sjögren’s syndrome: a rare diagnosis for nodular lung lesions. Int J Rheum Dis 2009; 12: 358–360.

89. Srinivas P, Liam CK, Jayaram G. Localised nodular pulmonary amyloidosis in a patient with sicca syndrome. Med J Malaysia 2000; 55: 385–387.

90. Kambouchner M, Godmer P, Guillevin L. Low grade marginal zone B cell lymphoma of the breast associated with localised amyloidosis and corpora amylacea in a woman with long standing primary Sjögren’s syndrome. J Clin Pathol 2003; 56: 74–77.

91. Khoor A, Myers JL, Tazelaar HD et al. Amyloid-like pulmonary nodules including localised light chain deposition: clinicopathologic analysis of three cases. Amer J Clin Pathol 2004; 121: 200–204.

92. Bhargava P, Rushin JM, Rusnock EJ et al. Pulmonary light chain deposition disease: report of five cases and review of the literature. Am J Surg Pathol 2007; 31: 267–276.

93. Yong HS, Woo OH, Lee JW et al. Primary localized amyloidosis manifested as supraclavicular and mediastinal lymphadenopathy. Br J Radiol 2007; 80: e131–e133.

94. Dalton HR, Featherstone T, Athanasou N. Organ limited amyloidosis with lymphadenopathy. Postgrad Med J 1992; 68: 47–50.

95. Kalra S, Utz JP, Edell ES et al. External-beam radiation therapy in the treatment of diffuse tracheobronchial amyloidosis. Mayo Clin Proc 2001; 76: 853–856.

96. Madden BP, Lee M, Paruchuru P. Successful treatment of endobronchial amyloidosis using Nd: YAG laser therapy as an alternative to lobectomy. Monaldi Arch Chest Dis 2001; 56: 27–29.

97. Monroe AT, Walia R, Zlotecki RA et al. Tracheobronchial amyloidosis: a case report of successful treatment with external beam radiation therapy. Chest 2004; 125: 784–789.

98. Neben-Wittich MA, Foote RL et al. External beam radiation therapy for tracheobronchial amyloidosis. Chest 2007; 132: 262–267.

99. Piazza C, Cavaliere S, Foccoli P et al. Endoscopic management of laryngo-tracheobronchial amyloidosis: a series of 32 patients. Eur Arch Otorhinolaryngol 2003; 260: 349–354.

100. Rubinow A, Celli BR, Cohen AS et al. Localized amyloidosis of the lower respiratory tract. Am Rev Respir Dis 1978; 118: 603–611.

101. Aylwin AC, Gishen P, Copley SJ. Imaging appearance of thoracic amyloidosis. J Thorac Imaging 2005; 20: 41–46.

102. Kim HY, Im JG, Song KS et al. Localized amyloidosis of the respiratory system: CT features. J Comput Assist Tomogr 1999; 23: 627–631.

103. Konietzko N. Amyloidoses of the lung. Pneumologie 2004; 58: 339–343.

104. Urban BA, Fishman EK, Goldman SM et al. CT evaluation of amyloidosis: spectrum of disease. Radiographics 1993; 13: 1295–1308.

105. Horger M, Lengerke C, Pfannenberg C et al. Significance of the “halo” sign for progression and regression of nodular pulmonary amyloidosis: radiographic-pathological correlation (2005:6b). Eur Radiol 2005; 15: 2037–2040.

106. Mysliveček M, Bačovský J, Ščudla V et al. 18F-FDG PET/CT and 99mTc-MIBI scintigraphy in evaluation of patients with multiple myeloma and monoclonal gammopathy of unknown significance: comparison of methods. Klin Onkol 2010; 23: 325–331.

107. Bačovský J, Mysliveček M, Ščudla V et al. Tc-99m MIBI scintigraphy in multiple myeloma: prognostic value of different Tc-99m MIBI uptake patterns. Clin Nucl Med 2010; 35: 667–670.

108. Umeda Y, Demura Y, Takeda N et al. FDG-PET findings of nodular pulmonary amyloidosis with a long-term observation. Nihon Kokyuki Gakkai Zasshi 2007; 45: 424–429.

109. Currie GP, Rossiter C, Dempsey OJ et al. Pulmonary amyloid and PET scanning. Respir Med 2005; 99: 1463–1464.

110. Grubstein A, Shitrit D, Sapir EE et al. Pulmonary amyloidosis: detection with PET-CT. Clin Nucl Med 2005; 30: 420–421.

111. Kung J, Zhuang H, Yu JQ et al. Intense fluorodeoxyglucose activity in pulmonary amyloid lesions on positron emission tomography. Clin Nucl Med 2003; 28: 975–976.

112. Ollenberger GP, Knight S, Tauro AJ. False-positive FDG positron emission tomography in pulmonary amyloidosis. Clin Nucl Med 2004; 29: 657–658.

113. Yadav S, Sharma S, Gilfillan I. Unusual positron emission tomography findings in pulmonary amyloidosis: a case report. J Cardiothorac Surg 2006; 1: 32.

114. Tan H, Guan Y, Zhao J et al. Findings of pulmonary amyloidosis on dual phase FDG PET/CT imaging. Clin Nucl Med 2010; 35: 206–207.

115. Sakata N, Hoshii Y, Nakamura T et al. Colocalization of apolipoprotein AI in various kinds of systemic amyloidosis. J Histochem Cytochem 2005; 53: 237–242.

116. Booth DR, Tan SY, Booth SE et al. A new apolipoprotein Al variant, Trp50Arg, causes hereditary amyloidosis. QJM 1995; 88: 695–702.

117. Röcken C, Shakespeare A. Pathology, diagnosis and pathogenesis of AA amyloidosis. Review. Virchows Arch 2002; 440: 111–122.

118. Sethi S, Theis JD, Leung N et al. Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. Clin J Am Soc Nephrol 2010; 5; 2180–2187.